Spots Global Cancer Trial Database for raynaud's phenomenon secondary to systemic sclerosis
Every month we try and update this database with for raynaud's phenomenon secondary to systemic sclerosis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis | NCT02228850 | Raynaud's Pheno... | Alprostadil Placebo | 18 Years - 79 Years | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | |
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) | NCT04040322 | Raynaud's Pheno... | Placebo IV infu... Iloprost Inject... | 18 Years - | Eicos Sciences, Inc. | |
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis | NCT02260557 | Raynaud's Pheno... | Selexipag Placebo | 18 Years - | Actelion | |
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) | NCT04040322 | Raynaud's Pheno... | Placebo IV infu... Iloprost Inject... | 18 Years - | Eicos Sciences, Inc. | |
A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis | NCT04915950 | Raynaud's Pheno... | Temanogrel Placebo | 18 Years - 75 Years | Pfizer | |
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3) | NCT04040322 | Raynaud's Pheno... | Placebo IV infu... Iloprost Inject... | 18 Years - | Eicos Sciences, Inc. | |
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis | NCT02228850 | Raynaud's Pheno... | Alprostadil Placebo | 18 Years - 79 Years | NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) | |
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis | NCT02260557 | Raynaud's Pheno... | Selexipag Placebo | 18 Years - | Actelion |